2-(benzo[b]thiophen-2-yl)-4,5-dihydro-1H-imidazole | 89197-30-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 2-(benzo[b]thiophen-2-yl)-4,5-dihydro-1H-imidazole
• 英文别名: 2-(2-benzothiophene-yl)-2-imidazoline；2-(1-benzothiophen-2-yl)-4,5-dihydro-1H-imidazole
• CAS: 89197-30-8
• 化学式: C₁₁H₁₀N₂S
• 分子量: 202.28
• InChiKey: STHDXGHJVQIACI-UHFFFAOYSA-N

物化性质

• 沸点：
  363.0±34.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  52.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯并噻吩-2-羧酸 在 盐酸 、 氯化亚砜 、 氨 、 phosphorus pentoxide 作用下， 以 1,4-二氧六环 、 乙醚 、 甲苯 、 苯 为溶剂， 反应 46.5h， 生成 2-(benzo[b]thiophen-2-yl)-4,5-dihydro-1H-imidazole
  参考文献：
  名称：

  .alpha.-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on .alpha.-adrenoreceptor activity

  摘要：

  Modification of the 1,4-benzodioxan ring present in RX 781094 has not previously been considered. This paper describes a number of analogues of this ring system, including compounds in which one of the oxygen atoms has been replaced by a methylene group and also those in which the ring size has been changed to give, for example, furan and thiophene derivatives. The dihydrobenzofuranylimidazoline compound 7 is the only analogue possessing presynaptic antagonist potency potency and selectivity comparable to that of 1. In view of this result, a number of derivatives was prepared to determine the structure-activity relationships within this series. Many derivatives, as well as the parent compound 7, were found to possess presynaptic alpha 2-adrenoreceptor antagonist and postsynaptic alpha 1-adrenoreceptor partial agonist properties. Two of the selective presynaptic antagonists, 13 and 14 possess greater potency and selectivity than that possessed by 1. The 5-chloro derivative 25 is twice as potent as after oral administration but only about half as potent when given intravenously.

  DOI：

  10.1021/jm00371a003

文献信息

• Hypoglycemic imidazoline compounds
  申请人：ELI LILLY AND COMPANY

  公开号：EP1266897A3

  公开（公告）日：2003-12-03

  This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.The compounds have the following formula: whereinX is -O-, -S-, or -NR5-;R5 is hydrogen, C1-8 alkyl, or an amino protecting group;R4 isY is -O-, -S-, or -NR8-;Y' is -O- or -S-;

  本发明涉及某些新型的咪唑啉化合物及其类似物，以及它们用于治疗糖尿病、糖尿病并发症、代谢紊乱或相关疾病中的糖利用受损情况，涉及包含它们的药物组合物，以及它们的制备过程。这些化合物的公式如下：其中X是-O-，-S-，或-NR5-；R5是氢，C1-8烷基，或氨基保护基团；R4是Y是-O-，-S-，或-NR8-；Y'是-O-或-S-；
• BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS
  申请人：United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command

  公开号：EP1945209A2

  公开（公告）日：2008-07-23
• ANTIVIRAL COMPOUNDS AND METHODS OF USING THEREOF
  申请人：The United States Of America, As Represented By The Secretary of the Army, on behalf of the U.S. Army Research Institute of Infectious Diseases

  公开号：EP2120952A2

  公开（公告）日：2009-11-25
• METHODS OF INHIBITING VIRAL INFECTION
  申请人：Functional Genetics, Inc.

  公开号：EP2207801A1

  公开（公告）日：2010-07-21
• Small Molecule Inhibitors of Botulinum Neurotoxins
  申请人：Bavari Sina

  公开号：US20070112049A1

  公开（公告）日：2007-05-17

  Disclosed herein are methods of inhibiting the activity of Botulinum neurotoxin A metalloprotease with the compounds disclosed herein. Also disclosed are methods of treating, inhibiting or preventing intoxication caused by bacteria of at least one bacterial strain in a subject, and pharmaceutical and cosmetic compositions comprising the compounds disclosed herein.